Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVITA Medical, Inc.RCEL · Entity 5905 | General Counsel | May 31, 2024 | June 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVITA Medical, Inc.
Report date May 31, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,951 |
Reported balance
After 2024-05-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-31 · Grant · Acquired 2,225 · Balance 45,951 F1: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 31, 2024 (the purchase date of the offering period). F2: Includes unvested RSUs |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 31, 2024 (the purchase date of the offering period).
F2: Includes unvested RSUs
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2024 Filed Jun 3, 2024 16:34 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 2,225 | $8.17 | $18,174.91 |
DisclosureSEC source: 0000950170-24-068048 · ownership.xml · nonDerivative · entry 1 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,951 F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 31, 2024 (the purchase date of the offering period). F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 31, 2024 (the purchase date of the offering period). F2 · balance_after: Includes unvested RSUs Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 17:51 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0000950170-24-002570 · ownership.xml · derivative · entry 2 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-03 F3 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date. Read SEC document |
| November 30, 2023 Filed Jan 5, 2024 17:51 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 1,469 | $9.06 | $13,309.14 |
DisclosureSEC source: 0000950170-24-002570 · ownership.xml · nonDerivative · entry 1 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,726 F1 · shares: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase which began July 1, 2023 and ended November 30, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Company's stock on November 30, 2023 (the purchase date of the offering period). F1 · price: These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase which began July 1, 2023 and ended November 30, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Company's stock on November 30, 2023 (the purchase date of the offering period). F2 · balance_after: Includes unvested RSUs Read SEC document |
| August 21, 2023 Filed Sep 8, 2023 17:36 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | SaleCommon Stock | 4,193 | $15.84 | $66,417.12 |
DisclosureSEC source: 0000950170-23-047331 · ownership.xml · nonDerivative · entry 1 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,257 F1 · kind: Shares sold in connection with payment of taxes incurred by the Reporting Person upon the vesting of RSUs F2 · balance_after: Includes unvested RSUs Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:38 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001209191-23-035442 · doc4.xml · derivative · entry 1 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: These Stock Options vest in three equal annual installments beginning on the date 12 months following the grant date. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 18:53 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 20,650 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001209191-22-041374 · doc4.xml · derivative · entry 2 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,650 Underlying: Common Stock · 20,650 shares Expires 2032-07-01 F3 · derivative.exercise_date: These Stock Options vest in four equal annual installments beginning on August 20, 2023. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 18:53 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 35,950 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-041374 · doc4.xml · nonDerivative · entry 1 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,450 F1 · price: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments beginning on August 20, 2023. F2 · balance_after: Includes unvested Restricted Stock Units. Read SEC document |
| July 06, 2021 Filed Sep 7, 2021 16:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 6,925 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001209191-21-054957 · doc4.xml · derivative · entry 3 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,925 Underlying: Common Stock · 6,925 shares Expires 2031-07-06 F3 · derivative.exercise_date: These Stock Options vest in four equal annual installments upon the satisfaction of certain performance-based vesting criteria with respect to the particular portion of such Stock Options. Read SEC document |
| July 06, 2021 Filed Sep 7, 2021 16:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 10,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-054957 · doc4.xml · nonDerivative · entry 1 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · price: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments upon the satisfaction of certain performance-based vesting criteria with respect to the particular portion of Restricted Stock Units. Read SEC document |
| July 06, 2021 Filed Jul 6, 2022 18:52 UTC Amendment | AVITA Medical, Inc. RCEL · Entity 5905 | GrantCommon Stock | 10,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-041372 · doc4a.xml · nonDerivative · entry 1 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · price: Reflects Restricted Stock Units, each representing a contingent right to be issued one share of Common Stock. These Restricted Stock Units vest in four equal annual installments upon the satisfaction of certain performance-based vesting criteria with respect to the particular portion of Restricted Stock Units. F2 · balance_after: This Form 4/A is being filed solely to correct an administrative error in the number of shares of Common Stock shown as beneficially held by the Reporting Person in her Form 4 filed on September 7, 2021 (the "Original Form 4"). All other information set forth in the Original Form 4 remains correct. Read SEC document |
| May 18, 2021 Filed Sep 7, 2021 16:05 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-21-054957 · doc4.xml · derivative · entry 2 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 4,400 shares Expires 2028-06-25 F2 · derivative.exercise_date: These Stock Options were originally granted on June 25, 2018 and vested on May 18, 2021, upon the satisfaction of a performance-based vesting condition. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 20:00 UTC | AVITA Medical, Inc. RCEL · Entity 5905 | GrantStock Options (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001209191-20-050216 · doc4.xml · derivative · entry 1 Shiroma Donna · CIK 0001816251 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,600 Underlying: Common Stock · 4,400 shares Expires 2018-06-25 F1 · security: These Stock Options were originally exercisable for ordinary shares of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020 (the "Scheme"), the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise have been exercisable. F2 · derivative.exercise_price: The exercise price was converted from A$5.9, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor to shares of the Issuer's Common Stock, using the exchange rate as in effect on the date of grant (June 25, 2018). The actual exercise price will be the Australian dollar amount regardless of the exchange rate on the date of grant or of exercise. F3 · date: On September 9, 2020, the performance-based vesting condition with respect to these 4,400 Stock Options was satisfied. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.